NorthStar Medical Radioisotopes says it welcomes the news from federal agencies that there is now an adequate supply of a key isotope used in thousands of medical imaging tests built
Marking Company’s progress in advancing innovative and environmentally sound production of diagnostic imaging and therapeutic radioisotopes for the United States and Wisconsin
SHINE partners with Missouri nuclear reactor to produce cancer drugs gazettextra.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from gazettextra.com Daily Mail and Mail on Sunday newspapers.
SHINE Medical announces irradiation agreement with University of Missouri Research Reactor (MURR)
Press releases may be edited for formatting or style | June 09, 2021 Molecular Imaging
Rating saved JANESVILLE, Wis., June 8, 2021 – SHINE Medical Technologies LLC today announced that it has entered a multi-year contract with the University of Missouri Research Reactor, or MURR®, for irradiation of ytterbium-176, the starting material for the production of lutetium-177 (Lu-177), a therapeutic isotope showing great promise for improving patient outcomes for a range of cancers. MURR s experienced team and reliable reactor make its irradiation services invaluable to SHINE as we commercialize our Lu-177, said Katrina Pitas, vice president and general manager of SHINE Therapeutics. MURR s high neutron flux will help us produce all the non-carrier-added Lu-177 we need to serve our rapidly growing customer base, treating a wide variety of cancers.